Comparison of Invasive Pancreatic Ductal Adenocarcinoma vs Intraductal Papillary Mucinous Neoplasm

Introduction: Current evidence on overall survival (OS) between invasive pancreatic ductal adenocarcinoma (PDAC) and intraductal papillary mucinous neoplasm (IPMN) is limited to single-center reports. We compared the characteristics, management, OS of PDAC vs IPMN using national US data. Method: Invasive or adult (≥18y) patients were identified in National Cancer Database (2004-2016). was assessed with Kaplan-Meier method stratified log-rank test. Results: included 101,190 (100,834 PDAC, 356 IPMN). A higher proportion had clinical N1 (36.8% 15.7%, P<0.001) M1 disease (41.2% 5.9%, P<0.001). lower underwent surgery (25.5% 80.3%, but a received chemotherapy (65.4% 46.1%, radiation (25.3% 20.5%, P=0.04). surgical margin-positive resection (23.0% 14.0%, P=0.001). The median for 8.3 33.4 months (Figure A). In analysis, N0M0 12.8 43.3 B), N1M0 11.5 17.0 C), while 4.0 7.0 D). both diagnoses, yielded improved OS, analysis demonstrated similar findings. Conclusions: more aggressive than IPMN, yet case metastasis equally poor. Excellent long-term achievable highly selected cases, efforts should focus facilitating treatment.